Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer CenterTroy Z. Horvat, Paul B. Chapman, Richard D. Carvajal et al.|Journal of Clinical Oncology|2015Cited by 1.1k
Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal MelanomaRichard D. Carvajal, Gary K. Schwartz, Jeffrey A. Sosman et al.|JAMA|2014Cited by 429
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue SarcomaMrinal M. Gounder, Albiruni Ryan Abdul Razak, Alona Zer et al.|Journal of Clinical Oncology|2016Cited by 165